Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop.
Cohen JD, Aspry KE, Brown AS, Foody JM, Furman R, Jacobson TA, Karalis DG, Kris-Etherton PM, Laforge R, O'Toole MF, Scott RD, Underberg JA, Valuck TB, Willard KE, Ziajka PE, Ito MK. Cohen JD, et al. Among authors: brown as. J Clin Lipidol. 2013 Nov-Dec;7(6):573-609. doi: 10.1016/j.jacl.2013.10.002. Epub 2013 Oct 12. J Clin Lipidol. 2013. PMID: 24314357
JCL Roundtable: health information technology in the management of lipoprotein disorders.
Brown WV, Brown AS, Aspry KE, Ito MK. Brown WV, et al. Among authors: brown as. J Clin Lipidol. 2014 Mar-Apr;8(2):137-47. doi: 10.1016/j.jacl.2013.12.009. Epub 2013 Dec 26. J Clin Lipidol. 2014. PMID: 24636174
These are the supply of effective and safe lipid-lowering drugs as well as the ability to closely monitor pertinent measures in our patients. ...I was joined in this Roundtable discussion by 3 health professionals who have had extensive experience with the applicati …
These are the supply of effective and safe lipid-lowering drugs as well as the ability to closely monitor pertinent measures i …
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. Davidson MH, et al. Among authors: brown wv, brown as. J Clin Lipidol. 2011 Sep-Oct;5(5):338-67. doi: 10.1016/j.jacl.2011.07.005. J Clin Lipidol. 2011. PMID: 21981835
What is sufficient drug therapy for lipoprotein elevations?
Brown WV, Brown AS, Toth PP, Underberg J. Brown WV, et al. Among authors: brown as. J Clin Lipidol. 2017 Nov-Dec;11(6):1300-1308. doi: 10.1016/j.jacl.2017.10.015. Epub 2017 Oct 31. J Clin Lipidol. 2017. PMID: 29102497 No abstract available.
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, Dixon DL, Saseen JJ, Soffer D. Robinson JG, et al. Among authors: brown as. J Clin Lipidol. 2019 Jul-Aug;13(4):525-537. doi: 10.1016/j.jacl.2019.05.005. Epub 2019 May 16. J Clin Lipidol. 2019. PMID: 31281070
Genetic effects on efficacy of lipid-lowering drugs.
Brown WV, Brown AS, Ference BA, Toth PP, Underberg JA. Brown WV, et al. Among authors: brown as. J Clin Lipidol. 2017 Sep-Oct;11(5):1112-1117. doi: 10.1016/j.jacl.2017.08.010. Epub 2017 Aug 24. J Clin Lipidol. 2017. PMID: 28943038 No abstract available.
606 results